ABBOTT LABORATORIES — Director's Dealing 2022

Aug 26, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2022-08-25

Reporting Person: MANNING JOSEPH J (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-25	Common shares without par value	M	23008	$44.40	Acquired	80143	Direct
2022-08-25	Common shares without par value	S	23008	$104.9941	Disposed	57135	Direct
2022-08-25	Common shares without par value	S	3890	$105.24	Disposed	53245	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-25	Option (right to buy)	$44.40	M	23008	Disposed	2027-02-16	Common Shares (23008)	Direct

Footnotes

F1: Since the date of the reporting person's last ownership report, he transferred 3,738 shares and employee stock options to purchase 69,500 shares in the aggregate to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.59 to $105.37, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.